Chelsea Therapeutics Receives FDA Guidance for a Northera(TM) (Droxidopa) NDA Resubmission With Study 306B

[at noodls] – Company to Resubmit NDA in Late Second Quarter 2013 Short-term Clinical Benefit Adequate to Support Approval Company to Host Conference Call Today at 9:00 AM ET CHARLOTTE, N.C., Feb. 20, 2013 (GLOBE NEWSWIRE) … more

View todays social media effects on CHTP

View the latest stocks trending across Twitter. Click to view dashboard

See who Chelsea is hiring next, click here to view